Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines

PharmacoEconomics
Volume 36, Issue 2, February 2018
https://link.springer.com/journal/40273/36/2/page/1

Editorial
Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines
Salah Ghabri, Irina Cleemput, Jean-Michel Josselin
Introduction
Providing scientific advice and recommendations for public decision making entails identifying, selecting and weighing evidence derived from multiple sources of information through a systematic approach, while taking into account ethical, cultural and societal factors. Integrated in the evaluation process are exchanges between regulatory agencies, private firms, scientific experts and government representatives.
In the case of drugs and medical devices, health technology assessment (HTA) agencies are increasingly commissioned to evaluate innovations in order to provide government with recommendations and advice on reimbursement and/or pricing. To undertake this task, HTA agencies [1, 2, 3, 4, 5, 6] in Europe and elsewhere have developed methodological guidelines on the economic evaluation of health technologies [7]. One component of these guidelines deals with ways for both manufacturers (pharmaceutical and medical device firms) and HTA agencies evaluators (modelers, economists and public health experts) to address uncertainty…